Unknown

Dataset Information

0

A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020.


ABSTRACT:

Background

It is unclear how acute coronavirus disease 2019 (COVID-19)-directed therapies are used in children with life-threatening COVID-19 in US hospitals. We described characteristics of children hospitalized in the intensive care unit or step-down unit (ICU/SDU) who received COVID-19-directed therapies and the specific therapies administered.

Methods

Between March 15, 2020 and December 27, 2020, children <18 years of age in the ICU/SDU with acute COVID-19 at 48 pediatric hospitals in the United States were identified. Demographics, laboratory values, and clinical course were compared in children who did and did not receive COVID-19-directed therapies. Trends in COVID-19-directed therapies over time were evaluated.

Results

Of 424 children in the ICU/SDU, 235 (55%) received COVID-19-directed therapies. Children who received COVID-19-directed therapies were older than those who did not receive COVID-19-directed therapies (13.3 [5.6-16.2] vs 9.8 [0.65-15.9] years), more had underlying medical conditions (188 [80%] vs 104 [55%]; difference = 25% [95% CI: 16% to 34%]), more received respiratory support (206 [88%] vs 71 [38%]; difference = 50% [95% CI: 34% to 56%]), and more died (8 [3.4%] vs 0). Of the 235 children receiving COVID-19-directed therapies, 172 (73%) received systemic steroids and 150 (64%) received remdesivir, with rising remdesivir use over the study period (14% in March/April to 57% November/December).

Conclusion

Despite the lack of pediatric data evaluating treatments for COVID-19 in critically ill children, more than half of children requiring intensive or high acuity care received COVID-19-directed therapies.

SUBMITTER: Schuster JE 

PROVIDER: S-EPMC8807297 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020.

Schuster Jennifer E JE   Halasa Natasha B NB   Nakamura Mari M   Levy Emily R ER   Fitzgerald Julie C JC   Young Cameron C CC   Newhams Margaret M MM   Bourgeois Florence F   Staat Mary A MA   Hobbs Charlotte V CV   Dapul Heda H   Feldstein Leora R LR   Jackson Ashley M AM   Mack Elizabeth H EH   Walker Tracie C TC   Maddux Aline B AB   Spinella Philip C PC   Loftis Laura L LL   Kong Michele M   Rowan Courtney M CM   Bembea Melania M MM   McLaughlin Gwenn E GE   Hall Mark W MW   Babbitt Christopher J CJ   Maamari Mia M   Zinter Matt S MS   Cvijanovich Natalie Z NZ   Michelson Kelly N KN   Gertz Shira J SJ   Carroll Christopher L CL   Thomas Neal J NJ   Giuliano John S JS   Singh Aalok R AR   Hymes Saul R SR   Schwarz Adam J AJ   McGuire John K JK   Nofziger Ryan A RA   Flori Heidi R HR   Clouser Katharine N KN   Wellnitz Kari K   Cullimore Melissa L ML   Hume Janet R JR   Patel Manish M   Randolph Adrienne G AG  

Journal of the Pediatric Infectious Diseases Society 20220501 5


<h4>Background</h4>It is unclear how acute coronavirus disease 2019 (COVID-19)-directed therapies are used in children with life-threatening COVID-19 in US hospitals. We described characteristics of children hospitalized in the intensive care unit or step-down unit (ICU/SDU) who received COVID-19-directed therapies and the specific therapies administered.<h4>Methods</h4>Between March 15, 2020 and December 27, 2020, children <18 years of age in the ICU/SDU with acute COVID-19 at 48 pediatric hosp  ...[more]

Similar Datasets

| S-EPMC11919585 | biostudies-literature
| S-EPMC10558416 | biostudies-literature
| S-EPMC9131739 | biostudies-literature
| S-EPMC9427250 | biostudies-literature
| S-EPMC10562984 | biostudies-literature
| S-EPMC7428691 | biostudies-literature
| S-EPMC7402103 | biostudies-literature
| S-EPMC8131881 | biostudies-literature
| S-EPMC5433056 | biostudies-literature
| S-EPMC10561306 | biostudies-literature